Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCAptAIN
2024-510744-31-00Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in giant cell arteritis (GCA) (3 arms), sponsored by Novartis. Primary endpoint: Sustained remission at Week 52. Started Jul 2024; status: completed.
02
Drugs
secukinumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2024-510744-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510744-31-00.